Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

fatido/E+ via Getty Images Alector, Inc. (NASDAQ:ALEC) has been able to complete enrollment of its phase 2 INVOKE-2 study, which is using AL002 for the treatment of patients with early-stage Alzheimer's Disease [AD]. With enrollment of this TREM2 activator complete, it expects to report results from this mid-stage study in Q4 of 2024. The thing is that not only is it possible that positive data could be achieved, but that the company is in the process of developing the most advanced TREM2 activator in c ...